First patient dosed in phase 3 TACTI-004 lung cancer trial
Filed with ASX · · 3 pages · English
Earlier from Immutep
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
- Immutep announces initial safety data from IMP761 phase 1
- Immutep Reports Promising New Data in Head and Neck Cancer
- Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
- Excellent Survival Data from INSIGHT-003 Trial in NSCLC
Later from Immutep
- First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
- Immutep to Participate in Upcoming Investor Conferences
- Immutep Quarterly Activities Report Q3 FY25
- Excellent Overall Survival in Head & Neck Cancer Patients
- Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep